COMMUNIQUÉ DE PRESSE
News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
MIRA Pharmaceuticals, Inc. selects neuropathic pain as the primary indication for its novel oral ketamine analog, Ketamir-2, targeting neurologic disorders. Pre-IND meeting with FDA anticipated in Nov 2024 -
COMMUNIQUÉ DE PRESSE
Nextech3D.ai Signs LOI to Acquire Designhubz Expanding its 3D & AR Portfolio With Try-On Technology For Wearables
Nextech3D.AI acquires Designhubz's AR try-on technology, enhancing immersive eCommerce experiences and personalization capabilities. CEO excited about the expanded market and strategic positioning -
-
COMMUNIQUÉ DE PRESSE
Electrical Geophysical Integration Reveals Upside at Piuquenes Cu–Au Porphyry Project, San Juan
Pampa Metals Corp. provides update on Piuquenes Cu-Au Project in Argentina, highlighting key findings from geophysical data integration and current activities for the upcoming field season -
COMMUNIQUÉ DE PRESSE
Hardman & Co Research on Shield Therapeutics (STX): Focusing on successful execution
Hardman & Co Research provides analysis on Shield Therapeutics (STX) focusing on successful execution. Shield progressing well with sales traction and cost control, aiming for cashflow-break even in 2H'25 -
COMMUNIQUÉ DE PRESSE
Santé Canada approuve (Pr)CABTREO(MC) (phosphate de clindamycine, adapalène et peroxyde de benzoyle), un traitement topique à triple combinaison pour l'acné vulgaire chez les patients âgés de 12 ans et plus
Bausch Health Canada Inc. annonce l'approbation par Santé Canada de PrCABTREO, traitement topique à triple combinaison pour l'acné vulgaire. Disponible Q4 2024
